{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:59:01Z","timestamp":1790279941799,"version":"4.1.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03477-5","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T20:44:12Z","timestamp":1781037852000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Identification of Counterfeit Biopharmaceuticals using Portable Fourier Transform Infrared Spectroscopy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2865-1065","authenticated-orcid":false,"given":"Vineela","family":"Peruri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6268-7766","authenticated-orcid":false,"given":"Rishika","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5864-9240","authenticated-orcid":false,"given":"Drashti","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-4244","authenticated-orcid":false,"given":"Anurag S.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"3477_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.copbio.2009.10.006","volume":"20","author":"SJ Shire","year":"2009","unstructured":"Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20:708\u201314. https:\/\/doi.org\/10.1016\/j.copbio.2009.10.006.","journal-title":"Curr Opin Biotechnol"},{"key":"3477_CR2","first-page":"24","volume":"1","author":"T Morrow","year":"2004","unstructured":"Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1:24\u20139.","journal-title":"Biotechnol Healthc"},{"key":"3477_CR3","unstructured":"Ferraro Andrew. Investment in Biopharma Facilities Continues. Pharama\u2019s almanac. 2016.https:\/\/www.pharmasalmanac.com\/articles\/investment-in-biopharma-facilities-continues. [accessed on January 2026]"},{"issue":"2","key":"3477_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/J.XPHS.2023.11.004","volume":"113","author":"K Sampathkumar","year":"2024","unstructured":"Sampathkumar K, Kerwin BA. Roadmap for drug product development and manufacturing of biologics. J Pharm Sci. 2024;113(2):314\u201331. https:\/\/doi.org\/10.1016\/J.XPHS.2023.11.004.","journal-title":"J Pharm Sci"},{"key":"3477_CR5","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.5821","author":"T Lapto\u0161","year":"2018","unstructured":"Lapto\u0161 T, Omersel J. The importance of handling high-value biologicals: Physico-chemical instability and immunogenicity of monoclonal antibodies (Review). Exp Ther Med. 2018. https:\/\/doi.org\/10.3892\/etm.2018.5821.","journal-title":"Exp Ther Med"},{"key":"3477_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075","volume":"9","author":"FD Makurvet","year":"2021","unstructured":"Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075. https:\/\/doi.org\/10.1016\/j.medidd.2020.100075.","journal-title":"Med Drug Discov"},{"key":"3477_CR7","unstructured":"Grand View Research. Monoclonal antibodies market size, share & trends analysis report by source type (chimeric, murine, humanized, human), by production type (in vivo, in vitro), by application, by end-use, by region, and segment forecasts. 2023. https:\/\/www.grandviewresearch.com\/industry-analysis\/monoclonal-antibodies-market.[accessed on January 2026]"},{"key":"3477_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4269\/ajtmh.14-0389","volume":"92","author":"TK Mackey","year":"2015","unstructured":"Mackey TK, Liang BA, York P, Kubic T. Counterfeit drug penetration into global legitimate medicine supply chains: a global assessment. Am J Trop Med Hyg. 2015;92:59\u201367. https:\/\/doi.org\/10.4269\/ajtmh.14-0389.","journal-title":"Am J Trop Med Hyg"},{"key":"3477_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2022.08.003","volume":"27","author":"H Omidian","year":"2022","unstructured":"Omidian H, Omidi Y. Drug counterfeiting and decentralized whistleblowers. Drug Discov Today. 2022;27:103335. https:\/\/doi.org\/10.1016\/j.drudis.2022.08.003.","journal-title":"Drug Discov Today"},{"key":"3477_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40290-023-00468-w","volume":"37","author":"R Pathak","year":"2023","unstructured":"Pathak R, Gaur V, Sankrityayan H, Gogtay J. Tackling counterfeit drugs: the challenges and possibilities. Pharmaceut Med. 2023;37:281\u201390. https:\/\/doi.org\/10.1007\/s40290-023-00468-w.","journal-title":"Pharmaceut Med"},{"key":"3477_CR11","unstructured":"ABMA JENNIFER. Bitter Biopharmaceuticals: Biologic Counterfeiting and Supply Chain Concerns. [San Diego]: University of San Diego ; 2017. https:\/\/digital.sandiego.edu\/ilj\/vol18\/iss1\/6\/ [accessed on January 2026]"},{"key":"3477_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1586\/17512433.1.3.333","volume":"1","author":"AI Wertheimer","year":"2008","unstructured":"Wertheimer AI. Identifying and combating counterfeit drugs. Expert Rev Clin Pharmacol. 2008;1:333\u20136. https:\/\/doi.org\/10.1586\/17512433.1.3.333.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3477_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/009885880603200207","volume":"32","author":"BA Liang","year":"2006","unstructured":"Liang BA. Fade to black: importation and counterfeit drugs. Am J Law Med. 2006;32:279\u2013323. https:\/\/doi.org\/10.1177\/009885880603200207.","journal-title":"Am J Law Med"},{"key":"3477_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1533\/9781908818041.327","volume-title":"An Introduction to Pharmaceutical Sciences","author":"J Roy","year":"2011","unstructured":"Roy J. Counterfeit drugs and drug abuse. In: An Introduction to Pharmaceutical Sciences. Elsevier; 2011. p. 327\u201348. https:\/\/doi.org\/10.1533\/9781908818041.327."},{"key":"3477_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.fsir.2022.100302","volume":"7","author":"P Karungamye","year":"2023","unstructured":"Karungamye P. Counterfeit and substandard drugs in Tanzania: a review. Forensic Sci Int Rep. 2023;7:100302. https:\/\/doi.org\/10.1016\/j.fsir.2022.100302.","journal-title":"Forensic Sci Int Rep"},{"key":"3477_CR16","unstructured":"World Health Organization. Substandard and falsified medical products. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/substandard-and-falsified-medical-products. 2024. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/substandard-and-falsified-medical-products. [accessed on January 2026]"},{"key":"3477_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s44395-025-00004-6","volume":"1","author":"A Raj","year":"2025","unstructured":"Raj A, Yadav T, Patil S, Kalra A, Sardana S, Nirbhavane P. Counterfeit medicine: a major public health concern and effective remedies for combatting the crisis. Discover Pharm Sci. 2025;1:4. https:\/\/doi.org\/10.1007\/s44395-025-00004-6.","journal-title":"Discover Pharm Sci"},{"key":"3477_CR18","unstructured":"PEW Health Group. Heparin: A wake-up call on risks to the U.S. drug supply. https:\/\/www.pewtrusts.org\/-\/media\/assets\/2012\/09\/13\/dspfactsheet1050912. 2012. [accessed on January 2026]."},{"key":"3477_CR19","unstructured":"Larry Greenemeier. Heparin Scare: Deaths from Tainted Blood-Thinner Spur Race for Safe Replacement. Scientific American, https:\/\/www.scientificamerican.com\/article\/heparin-scare-deaths\/. 2008. [accessed on January 2026]"},{"key":"3477_CR20","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1182\/blood.V106.11.2251.2251","volume":"106","author":"DW Raisch","year":"2005","unstructured":"Raisch DW, Bennett CL, Nebeker J, Jakiche R, Carson K. Counterfeit Epoetin: a review of MedWatch data. Blood. 2005;106:2251\u20132251. https:\/\/doi.org\/10.1182\/blood.V106.11.2251.2251.","journal-title":"Blood"},{"key":"3477_CR21","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1200\/JOP.2011.000325","volume":"8","author":"ZP Qureshi","year":"2012","unstructured":"Qureshi ZP, Norris L, Sartor O, McKoy JM, Armstrong J, Raisch DW, et al. Caveat oncologist: clinical findings and consequences of distributing counterfeit erythropoietin in the United States. J Oncol Pract. 2012;8:84\u201390. https:\/\/doi.org\/10.1200\/JOP.2011.000325.","journal-title":"J Oncol Pract"},{"key":"3477_CR22","unstructured":"Christophe Gattuso. Fake GLP-1 Drugs Go Viral: France Launches Crackdown. Medscape, https:\/\/www.medscape.com\/viewarticle\/fake-glp-1-drugs-go-viral-france-launches-crackdown-2025a1000rt1. 2015."},{"key":"3477_CR23","unstructured":"U.S. Food Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain. 2025. [accessed on January 2026]"},{"key":"3477_CR24","unstructured":"Miller. I. Henry. Fraud in your pill bottle: The unacceptable cost of counterfeit medicines. Pcaific Research Institute. 2020. https:\/\/www.pacificresearch.org\/new-brief-counterfeit-drugs-harm-patients-economy-innovation\/ [accessed on January 2026]"},{"key":"3477_CR25","unstructured":"Jyrki Berg. The Economic Impact of Counterfeit Healthcare Products, https:\/\/truemedinc.com\/blog\/the-economic-impact-of-counterfeit-healthcare-products\/. True Med, . 2024. https:\/\/truemedinc.com\/blog\/the-economic-impact-of-counterfeit-healthcare-products\/. True Med, [accessed on January 2026]."},{"key":"3477_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021825","volume":"8","author":"AT Mori","year":"2018","unstructured":"Mori AT, Meena E, Kaale EA. Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority. BMJ Open. 2018;8:e021825. https:\/\/doi.org\/10.1136\/bmjopen-2018-021825.","journal-title":"BMJ Open"},{"key":"3477_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4269\/ajtmh.21-1133","volume":"107","author":"S Ozawa","year":"2022","unstructured":"Ozawa S, Higgins CR, Nwokike JI, Phanouvong S. Modeling the health and economic impact of substandard and falsified medicines: a review of existing models and approaches. Am J Trop Med Hyg. 2022;107:14\u201320. https:\/\/doi.org\/10.4269\/ajtmh.21-1133.","journal-title":"Am J Trop Med Hyg"},{"key":"3477_CR28","unstructured":"NIH SEED Innovator Support Team. Regulatory knowledge guide for biological products. National Institutes of Health. 2024. https:\/\/seed.nih.gov\/sites\/default\/files\/2024-03\/Regulatory-Knowledge-Guide-Biological-Products.pdf [accessed on January 2026]"},{"key":"3477_CR29","unstructured":"Argenx. Licensure and Regulation of Biologics in the U.S. 2024. https:\/\/reports.argenx.com\/2024\/argenx-group\/regulation\/licensure-and-regulation-of-biologics-in-the-u-s.html [accessed on January 2026]"},{"key":"3477_CR30","unstructured":"Amanda K. Sarata HZS. Medical Product Regulation: Drugs, Biologics, and Devices. Congressional Research Sevice. 2023. https:\/\/www.everycrsreport.com\/reports\/IF11083.html. [accessed on January 2026]"},{"issue":"2","key":"3477_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.24926\/iip.v9i2.966","volume":"9","author":"PCNS Le","year":"2018","unstructured":"Le PCNS, Grund L, Marwa J, Otts J, Ojo W, Arab F. Combating substandard and counterfeit medicines by securing the pharmaceutical supply chain. Innov Pharm. 2018;9:13. https:\/\/doi.org\/10.24926\/iip.v9i2.966.","journal-title":"Innov Pharm"},{"key":"3477_CR32","unstructured":"Drug supply chain security act (DSCSA). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/drug-supply-chain-integrity\/drug-supply-chain-security-act-dscsa. [accessed on January 2026]"},{"key":"3477_CR33","unstructured":"Mikson Christopher KJ. Certain DSCSA deadline extensions set to eclipse in 2025. DLA Piper. 2025. https:\/\/www.dlapiper.com\/insights\/publications\/2025\/01\/certain-dscsa-deadline-extensions-set-to-eclipse-in-2025 [accessed on January 2026]"},{"key":"3477_CR34","unstructured":"U.S. FDA Announces Enforcement Discretion for Drug Supply Chain Security Act Enhanced Drug Distribution Security Requirements. Sidley Insights. 2023. https:\/\/www.sidley.com\/en\/insights\/newsupdates\/2023\/08\/us-fda-announces-enforcement-discretion-for-dscsa-enhanced-drug-distribution-security-requirements, [accessed on January 2026]"},{"key":"3477_CR35","unstructured":"DIRECTIVE 2011\/62\/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. Official Journal of the European Union . 2011. https:\/\/health.ec.europa.eu\/document\/download\/7bd5d800-08de-47a3-be9f-d5832682c262_en, [accessed on January 2026]"},{"key":"3477_CR36","unstructured":"BIO comments on key ideas for better protection of patients against the risk of counterfeit medicines. Biotechnology Industry Organization. 2008. https:\/\/health.ec.europa.eu\/document\/download\/ca1b810e-34ba-4eef-a995-64418a0f14cf_en [accessed on January 2026]"},{"key":"3477_CR37","unstructured":"Falsified medicines: reporting obligations. European Medicines Agency. \nhttps:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/compliance-post-authorisation\/falsified-medicines-reporting-obligations.[accessed on January 2026]"},{"key":"3477_CR38","unstructured":"Chow DCK. Barriers to criminal enforcement against counterfeiting in China. Vanderbilt Journal of Entertainment & Technology Law, . 2022;633\u201372. https:\/\/scholarship.law.vanderbilt.edu\/jetlaw\/vol24\/iss4\/1\/ [accessed on January 2026]"},{"key":"3477_CR39","unstructured":"Drug Administration Law\u2002of the People\u2019s Republic of China. National Medical Products Administration, China . 2019. . https:\/\/english.nmpa.gov.cn\/2019-09\/26\/c_773012.htm. [accessed on January 2026]"},{"key":"3477_CR40","doi-asserted-by":"publisher","first-page":"9","DOI":"10.22270\/ijdra.v10i2.515","volume":"10","author":"S Singh","year":"2022","unstructured":"Singh S, Gupta P. A comprehensive study on counterfeit medicine and its prevention in India through its regulatory approach. Int J Drug Regul Aff. 2022;10:9\u201313. https:\/\/doi.org\/10.22270\/ijdra.v10i2.515.","journal-title":"Int J Drug Regul Aff"},{"key":"3477_CR41","doi-asserted-by":"publisher","first-page":"115","DOI":"10.4103\/ajprhc.ajprhc_39_23","volume":"15","author":"LP Nori","year":"2023","unstructured":"Nori LP, Srinivas Varma T, Nulu LSNV, Venkateswara Raju K. A study of regulations combating counterfeit medicines across India, USA, and Europe. Asian J Pharm Res Health Care. 2023;15:115\u201323. https:\/\/doi.org\/10.4103\/ajprhc.ajprhc_39_23.","journal-title":"Asian J Pharm Res Health Care"},{"key":"3477_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1708784","author":"B Chabalenge","year":"2025","unstructured":"Chabalenge B, Sahota T, Ermolina I, Tanna S. Substandard and falsified medicines in Africa: healthcare systems challenges, supply chain issues, regulatory challenges and strategies to increase access to quality medicines. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1708784.","journal-title":"Front Pharmacol"},{"key":"3477_CR43","unstructured":"Battling Counterfeit Medicines in Africa: Leveraging Technology for a Safer Supply Chain. Cosmo Trace. 2024.\u00a0https:\/\/blog.cosmotrace.com\/serialization\/battling-counterfeit-medicines-in-africa-leveraging-technology-for-a-safer-supply-chai. [accessed on January 2026]"},{"key":"3477_CR44","doi-asserted-by":"publisher","first-page":"246","DOI":"10.37394\/23209.2024.21.24","volume":"21","author":"A Pesqueira","year":"2024","unstructured":"Pesqueira A, Sousa MJ, Machado ADB. Addressing counterfeiting and fraud concerns in healthcare packaging and labeling with blockchain: opportunities and challenges. WSEAS TRANSACTIONS ON INFORMATION SCIENCE AND APPLICATIONS. 2024;21:246\u201363. https:\/\/doi.org\/10.37394\/23209.2024.21.24.","journal-title":"WSEAS TRANSACTIONS ON INFORMATION SCIENCE AND APPLICATIONS"},{"key":"3477_CR45","doi-asserted-by":"publisher","unstructured":"shruthi k ,\u00a0Poornima AS (2024) An Approach Based on Blockchain Technology to Confirm the Counterfeit-Free Pharmaceutical Supply Chain.\u00a0https:\/\/doi.org\/10.2139\/ssrn.4888850","DOI":"10.2139\/ssrn.4888850"},{"key":"3477_CR46","doi-asserted-by":"publisher","first-page":"4870","DOI":"10.1007\/s11227-023-05654-w","volume":"80","author":"N Sharma","year":"2024","unstructured":"Sharma N, Rohilla R. A multilevel authentication-based blockchain powered medicine anti-counterfeiting for reliable IoT supply chain management. J Supercomput. 2024;80:4870\u2013913. https:\/\/doi.org\/10.1007\/s11227-023-05654-w.","journal-title":"J Supercomput"},{"key":"3477_CR47","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.62225\/2583049X.2024.4.6.4103","volume":"4","author":"SK Adeyemo","year":"2024","unstructured":"Adeyemo SK, Mbata OA, Balogun DO. Combating counterfeit drugs in the U.S. pharmaceutical supply chain: the potential of blockchain and IoT for public health safety. International Journal of Advanced Multidisciplinary Research and Studies. 2024;4:1730\u20139. https:\/\/doi.org\/10.62225\/2583049X.2024.4.6.4103.","journal-title":"International Journal of Advanced Multidisciplinary Research and Studies"},{"key":"3477_CR48","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/14712598.2013.783560","volume":"13","author":"N Casadevall","year":"2013","unstructured":"Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, et al. Pharmacovigilance and biosimilars: Considerations, needs and challenges. Expert Opin Biol Ther. 2013;13:1039\u201347. https:\/\/doi.org\/10.1517\/14712598.2013.783560.","journal-title":"Expert Opin Biol Ther"},{"key":"3477_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.forsciint.2017.07.012","volume":"278","author":"K D\u00e9gardin","year":"2017","unstructured":"D\u00e9gardin K, Desponds A, Roggo Y. Protein-based medicines analysis by Raman spectroscopy for the detection of counterfeits. Forensic Sci Int. 2017;278:313\u201325. https:\/\/doi.org\/10.1016\/j.forsciint.2017.07.012.","journal-title":"Forensic Sci Int"},{"key":"3477_CR50","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1016\/j.xphs.2021.03.011","volume":"110","author":"Z Akhunzada","year":"2021","unstructured":"Akhunzada Z, Wu Y, Haby T, Jayawickrama D, McGeorge G, La Colla M, et al. Analysis of biopharmaceutical formulations by Time Domain Nuclear Magnetic Resonance (TD-NMR) spectroscopy: A potential method for detection of counterfeit biologic pharmaceuticals. J Pharm Sci. 2021;110:2765\u201370. https:\/\/doi.org\/10.1016\/j.xphs.2021.03.011.","journal-title":"J Pharm Sci"},{"key":"3477_CR51","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/nprot.2016.036","volume":"11","author":"HJ Butler","year":"2016","unstructured":"Butler HJ, Ashton L, Bird B, Cinque G, Curtis K, Dorney J, et al. Using Raman spectroscopy to characterize biological materials. Nat Protoc. 2016;11:664\u201387. https:\/\/doi.org\/10.1038\/nprot.2016.036.","journal-title":"Nat Protoc"},{"key":"3477_CR52","unstructured":"Kalyanaraman Ravi, Chauhan Mitesh. Screening and detecting counterfeit biologics drugs. Biopharma Asia. 2013 Jan; https:\/\/biopharma-asia.com\/magazine-articles\/screening-and-detecting-counterfeit-biologics-drugs\/ [accessed on January 2026]"},{"key":"3477_CR53","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.talanta.2006.12.023","volume":"72","author":"J Luypaert","year":"2007","unstructured":"Luypaert J, Massart DL, Vander Heyden Y. Near-infrared spectroscopy applications in pharmaceutical analysis. Talanta. 2007;72:865\u201383. https:\/\/doi.org\/10.1016\/j.talanta.2006.12.023.","journal-title":"Talanta"},{"key":"3477_CR54","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1039\/C4CS00062E","volume":"43","author":"M Manley","year":"2014","unstructured":"Manley M. Near-infrared spectroscopy and hyperspectral imaging: non-destructive analysis of biological materials. Chem Soc Rev. 2014;43:8200\u201314. https:\/\/doi.org\/10.1039\/C4CS00062E.","journal-title":"Chem Soc Rev"},{"key":"3477_CR55","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2116\/analsci.20.1339","volume":"20","author":"YP Du","year":"2004","unstructured":"Du YP, Liang YZ, Kasemsumran S, Maruo K, Ozaki Y. Removal of interference signals due to water from in vivo near-infrared (NIR) spectra of blood glucose by region orthogonal signal correction (ROSC). Anal Sci. 2004;20:1339\u201345. https:\/\/doi.org\/10.2116\/analsci.20.1339.","journal-title":"Anal Sci"},{"key":"3477_CR56","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00216-004-2569-2","volume":"379","author":"D Chen","year":"2004","unstructured":"Chen D, Hu B, Shao X, Su Q. Removal of major interference sources in aqueous near-infrared spectroscopy techniques. Anal Bioanal Chem. 2004;379:143\u20138. https:\/\/doi.org\/10.1007\/s00216-004-2569-2.","journal-title":"Anal Bioanal Chem"},{"key":"3477_CR57","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/elps.202100045","volume":"42","author":"MA Afzal","year":"2021","unstructured":"Afzal MA, Bhojane PP, Rathore AS. A simple, rapid, and robust \u201con\u2010the\u2010go\u201d identity testing of biotherapeutics using FTIR spectroscopy. Electrophoresis. 2021;42:1655\u201364. https:\/\/doi.org\/10.1002\/elps.202100045.","journal-title":"Electrophoresis"},{"key":"3477_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2021.119710","volume":"255","author":"M Mittal","year":"2021","unstructured":"Mittal M, Sharma K, Rathore A. Checking counterfeiting of pharmaceutical products by attenuated total reflection mid-infrared spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc. 2021;255:119710. https:\/\/doi.org\/10.1016\/j.saa.2021.119710.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"3477_CR59","doi-asserted-by":"publisher","unstructured":"M R L, Ahmed M N S, Khan S (2021) Block Chain Based Supply Chain Management for Counterfeit Drugs in Pharmaceutical Industry. Int J Sci Res Compt Sci Eng Inform Technol 100\u20138. https:\/\/doi.org\/10.32628\/CSEIT217122","DOI":"10.32628\/CSEIT217122"},{"key":"3477_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.fuel.2024.132701","volume":"376","author":"S Khalighi","year":"2024","unstructured":"Khalighi S, Ma L, Ren S, Varveri A. Evaluating the impact of data pre-processing methods on classification of ATR-FTIR spectra of bituminous binders. Fuel. 2024;376:132701. https:\/\/doi.org\/10.1016\/j.fuel.2024.132701.","journal-title":"Fuel"},{"key":"3477_CR61","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1038\/s41598-020-62740-2","volume":"10","author":"P Koziol","year":"2020","unstructured":"Koziol P, Raczkowska MK, Skibinska J, Urbaniak-Wasik S, Paluszkiewicz C, Kwiatek W, et al. Comparison of spectral and spatial denoising techniques in the context of High Definition FT-IR imaging hyperspectral data. Sci Rep. 2020;10:5699. https:\/\/doi.org\/10.1038\/s41598-020-62740-2.","journal-title":"Sci Rep"},{"key":"3477_CR62","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1366\/12-06723","volume":"67","author":"B Zimmermann","year":"2013","unstructured":"Zimmermann B, Kohler A. Optimizing Savitzky\u2013Golay parameters for improving spectral resolution and quantification in infrared spectroscopy. Appl Spectrosc. 2013;67:892\u2013902. https:\/\/doi.org\/10.1366\/12-06723.","journal-title":"Appl Spectrosc"},{"key":"3477_CR63","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/fam.810190505","volume":"19","author":"H Pottel","year":"1995","unstructured":"Pottel H. The use of partial least squares (PLS) in quantitative FTIR: determination of gas concentrations in smoke gases of burning textiles. Fire Mater. 1995;19:221\u201331. https:\/\/doi.org\/10.1002\/fam.810190505.","journal-title":"Fire Mater"},{"key":"3477_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodcont.2024.110996","volume":"169","author":"R Fakhlaei","year":"2025","unstructured":"Fakhlaei R, Babadi AA, Ariffin NM, Xiaobo Z. Development of FTIR-ATR spectra and PLS regression combination model for discrimination of pure and adulterated acacia honey. Food Control. 2025;169:110996. https:\/\/doi.org\/10.1016\/j.foodcont.2024.110996.","journal-title":"Food Control"},{"key":"3477_CR65","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40259-020-00404-3","volume":"34","author":"S Joshi","year":"2020","unstructured":"Joshi S, Rathore AS. Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study. BioDrugs. 2020;34:209\u201323. https:\/\/doi.org\/10.1007\/s40259-020-00404-3.","journal-title":"BioDrugs"},{"key":"3477_CR66","unstructured":"Agilent. Agilent Micro Lab Software: Operation Manual. https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/0020-410_MicroLab_Software_Manual.pdf [accessed on January 2026]."},{"key":"3477_CR67","doi-asserted-by":"publisher","first-page":"18052","DOI":"10.1021\/acs.analchem.4c03594","volume":"96","author":"W Ahmed","year":"2024","unstructured":"Ahmed W, Osborne EL, Veluthandath AV, Senthil MG. A Rapid and Simplified Approach to Correct Atmospheric Absorptions in Infrared Spectra. Anal Chem. 2024;96:18052\u201360. https:\/\/doi.org\/10.1021\/acs.analchem.4c03594.","journal-title":"Anal Chem"},{"key":"3477_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/J.SAA.2019.117373","volume":"223","author":"P Bru\u017adziak","year":"2019","unstructured":"Bru\u017adziak P. Vapor correction of FTIR spectra \u2013 a simple automatic least squares approach. Spectrochim Acta A Mol Biomol Spectrosc. 2019;223:117373. https:\/\/doi.org\/10.1016\/J.SAA.2019.117373.","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"3477_CR69","unstructured":"Agilent. Agilent 4500 Series FTIR: Operation Manual. https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/0021-401_4500FTIR_Manual_EN.pdf. [accessed on January 2026]"},{"key":"3477_CR70","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.3390\/ijms150610018","volume":"15","author":"Y Zou","year":"2014","unstructured":"Zou Y, Ma G. A New Criterion to Evaluate Water Vapor Interference in Protein Secondary Structural Analysis by FTIR Spectroscopy. Int J Mol Sci. 2014;15:10018\u201333. https:\/\/doi.org\/10.3390\/ijms150610018.","journal-title":"Int J Mol Sci"},{"key":"3477_CR71","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00432-021-03628-0","volume":"148","author":"M Hummel","year":"2022","unstructured":"Hummel M, Bosje T, Shaw A, Liu MS, Barve A, Kothekar M, et al. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. J Cancer Res Clin Oncol. 2022;148:487\u201396. https:\/\/doi.org\/10.1007\/s00432-021-03628-0.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3477_CR72","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1177\/19322968211058482","volume":"17","author":"G Vishwakarma","year":"2023","unstructured":"Vishwakarma G, Nupur N, Rathore AS. Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars. J Diabetes Sci Technol. 2023;17:417\u201327. https:\/\/doi.org\/10.1177\/19322968211058482.","journal-title":"J Diabetes Sci Technol"},{"key":"3477_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/19420862.2017.1402996","volume":"10","author":"N Nupur","year":"2018","unstructured":"Nupur N, Chhabra N, Dash R, Rathore AS. Assessment of structural and functional similarity of biosimilar products: Rituximab as a case study. MAbs. 2018;10:143\u201358. https:\/\/doi.org\/10.1080\/19420862.2017.1402996.","journal-title":"MAbs"},{"key":"3477_CR74","doi-asserted-by":"publisher","first-page":"6559","DOI":"10.1007\/s00216-013-7469-x","volume":"406","author":"MJ Levy","year":"2014","unstructured":"Levy MJ, Gucinski AC, Sommers CD, Ghasriani H, Wang B, Keire DA, et al. Analytical techniques and bioactivity assays to compare the structure and function of filgrastim (granulocyte-colony stimulating factor) therapeutics from different manufacturers. Anal Bioanal Chem. 2014;406:6559\u201367. https:\/\/doi.org\/10.1007\/s00216-013-7469-x.","journal-title":"Anal Bioanal Chem"},{"key":"3477_CR75","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/jps.21546","volume":"98","author":"SS Park","year":"2009","unstructured":"Park SS, Park J, Ko J, Chen L, Meriage D, Crouse-Zeineddini J, et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. J Pharm Sci. 2009;98:1688\u201399. https:\/\/doi.org\/10.1002\/jps.21546.","journal-title":"J Pharm Sci"},{"key":"3477_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.vibspec.2024.103726","volume":"134","author":"\u0110 Tintor","year":"2024","unstructured":"Tintor \u0110, Ninkovi\u0107 K, Milo\u0161evi\u0107 J, Polovi\u0107 N\u0110. Gaining insight into protein structure via ATR-FTIR spectroscopy. Vib Spectrosc. 2024;134:103726. https:\/\/doi.org\/10.1016\/j.vibspec.2024.103726.","journal-title":"Vib Spectrosc"},{"key":"3477_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2025.124518","volume":"1254","author":"N Garg","year":"2025","unstructured":"Garg N, Mendiratta S, Bindra G, Gehlot S, Goswami K, Kamal CM. Estimation of protein aggregates in Darbepoetin alfa formulations by developing a single validated analytical method. J Chromatogr B. 2025;1254:124518. https:\/\/doi.org\/10.1016\/j.jchromb.2025.124518.","journal-title":"J Chromatogr B"},{"key":"3477_CR78","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpba.2013.04.031","volume":"83","author":"A Harazono","year":"2013","unstructured":"Harazono A, Hashii N, Kuribayashi R, Nakazawa S, Kawasaki N. Mass spectrometric glycoform profiling of the innovator and biosimilar erythropoietin and darbepoetin by LC\/ESI-MS. J Pharm Biomed Anal. 2013;83:65\u201374. https:\/\/doi.org\/10.1016\/j.jpba.2013.04.031.","journal-title":"J Pharm Biomed Anal"},{"key":"3477_CR79","doi-asserted-by":"publisher","first-page":"6569","DOI":"10.1007\/s00216-014-7887-4","volume":"406","author":"AS Rathore","year":"2014","unstructured":"Rathore AS, Bhambure R. Establishing analytical comparability for \u201cbiosimilars\u201d: filgrastim as a case study. Anal Bioanal Chem. 2014;406:6569\u201376. https:\/\/doi.org\/10.1007\/s00216-014-7887-4.","journal-title":"Anal Bioanal Chem"},{"key":"3477_CR80","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","volume":"15","author":"F Kazazi-Hyseni","year":"2010","unstructured":"Kazazi-Hyseni F, Beijnen JH, Schellens JHM. Bevacizumab. Oncologist. 2010;15:819\u201325. https:\/\/doi.org\/10.1634\/theoncologist.2009-0317.","journal-title":"Oncologist"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03477-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03477-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03477-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:03:49Z","timestamp":1790276629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03477-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":80,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3477"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03477-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We declare that we have no financial and personal relationships with other people or organizations that can inappropriately influence our work, and there is no conflict of interest regarding the publication of this paper.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"231"}}